NB Health Laboratory Co. Ltd.

NB Health Laboratory Co. Ltd. is a Japanese biopharmaceutical company specializing in antibody drug development and innovative therapeutic solutions. Founded in 2006 in Sapporo, Japan, NB Health Laboratory Co.

Ltd. focuses on the discovery and production of antibodies for drug development. The company has completed 4 deals, with its most recent funding round being Series C in April 2022, raising JPY 83 million from Healthcare Innovation. The company's founder, Kiyoshi Takayama, has been instrumental in its strategic direction and growth, although prior details about other ventures are not available.

NBHL Co. Ltd. specializes in antibody drug development, focusing on the discovery and production of functional antibodies targeting G protein-coupled receptors (GPCRs). Their primary offering, the MoGRAA® Discovery Engine, enables innovative drug modalities that stand apart from traditional low-molecular weight compounds.

This technology aims to address unmet medical needs across various therapeutic areas, enhancing the efficacy of drug candidates in clinical applications. The client base includes pharmaceutical companies and research institutions requiring advanced solutions for drug discovery and development, primarily targeting global markets in North America and Asia. NBHL's revenue structure is primarily derived from partnerships and collaborations with pharmaceutical entities, academic institutions, and biotech companies. The company engages in B2B transactions, providing access to its MoGRAA® technology along with associated research services.

Revenue is generated through service agreements that include milestone payments tied to drug development progress, licensing arrangements for proprietary technologies, or project-based fees, emphasizing their focus on functional antibodies and GPCR-targeted pipelines within the biopharmaceutical landscape. In April 2022, NB Health Laboratory Co. Ltd. raised JPY 83 million in Series C funding from Healthcare Innovation.

This funding is aimed at accelerating the preclinical and clinical development of their antibody drug discovery platform. The company is actively working on new product developments and aims to expand into additional markets, particularly in North America and Asia, where there is a significant demand for advanced therapeutic agents.